Influence of corneal cross-linking for keratoconus on several objective parameters of dry eye.

Abstract

PURPOSE:

To evaluate the potential influence of corneal cross-linking (CXL) with ultraviolet-A light and riboflavin in keratoconic eyes on several objective parameters of dry eye syndrome.

METHODS:

This prospective single center study included 30 consecutive eyes of 16 patients that underwent CXL with riboflavin and ultraviolet-A treatment (epithelial removal, 30 minutes soaking with riboflavin, 30 minutes of illumination with 365 nm, 3 mW/cm(2), 5 cm distance). Several dry eye syndrome parameters were evaluated preoperatively and 3 and 6 months after the procedure: intra-individual comparison of fluorescein and Rose bengal staining, height of tear film meniscus, and tear film break-up time.

RESULTS:

Pathologic staining (more than 10 point-shaped areas or diffuse staining) with fluorescein was evident before CXL in 1 eye, 3 months after CXL in 1 eye, and 6 months after CXL in 1 eye. Rose bengal staining 3 and 6 months postoperatively was comparable to preoperative staining. Tear film height was reduced in 2 eyes before CXL and in 4 eyes 3 months postoperatively, and was normal in all eyes after 6 months. The number of eyes with reduced tear film break-up time was not significantly changed.

CONCLUSIONS:

CXL had no significant impact on several parameters of dry eye syndrome 3 and 6 months postoperatively.

• Authors: Suphi Taneri, Saskia Oehler, George Asimellis, A John Kanellopoulos
• Journal: Journal of refractive surgery (Thorofare, N.J. : 1995) (J Refract Surg) Vol. 29 Issue 9 Pg. 612-6 (Sep 2013) ISSN: 1081-597X [Print] United States
• PMID: 24016346 (Publication Type: Comparative Study, Journal Article)
• Copyright: Copyright 2013, SLACK Incorporated.

Chemical References

• Cross-Linking Reagents
• Photosensitizing Agents
• Riboflavin

Topics

• Adult
• Corneal Topography
• Cross-Linking Reagents (therapeutic use)
• Dry Eye Syndromes (complications, drug therapy, pathology)
• Female
• Follow-Up Studies
• Humans
• Keratoconus (complications, drug therapy, pathology)
• Male
• Middle Aged
• Photochemotherapy
• Photosensitizing Agents (therapeutic use)
• Prospective Studies
• Riboflavin (therapeutic use)
• Treatment Outcome
• Ultraviolet Rays
• Visual Acuity
• Young Adult